UY36741A - Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales - Google Patents

Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales

Info

Publication number
UY36741A
UY36741A UY0001036741A UY36741A UY36741A UY 36741 A UY36741 A UY 36741A UY 0001036741 A UY0001036741 A UY 0001036741A UY 36741 A UY36741 A UY 36741A UY 36741 A UY36741 A UY 36741A
Authority
UY
Uruguay
Prior art keywords
tbi
compositions
steroid
conmotions
composite
Prior art date
Application number
UY0001036741A
Other languages
English (en)
Inventor
Lu Xia
Zhang Yanfeng
Daniel E Levy
Lewandowski Michael
Original Assignee
Prevacus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevacus Inc filed Critical Prevacus Inc
Publication of UY36741A publication Critical patent/UY36741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a los compuestos de esteroide C-20, sus composiciones y métodos de uso para tratar, minimizar y/o evitar las lesiones cerebrales traumáticas (TBI), que incluyen TBI grave, TBI moderada y TBI leve, incluyendo las conmociones cerebrales
UY0001036741A 2015-06-21 2016-06-20 Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales UY36741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562182583P 2015-06-21 2015-06-21

Publications (1)

Publication Number Publication Date
UY36741A true UY36741A (es) 2016-12-30

Family

ID=57586267

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036741A UY36741A (es) 2015-06-21 2016-06-20 Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales

Country Status (4)

Country Link
EP (1) EP3416651A1 (es)
AR (1) AR105075A1 (es)
UY (1) UY36741A (es)
WO (1) WO2016209847A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
HRP20200995T1 (hr) 2013-04-17 2020-11-27 Sage Therapeutics, Inc. 19-nor neuroaktivni steroidi za metode liječenja
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
HRP20190232T1 (hr) 2013-04-17 2019-03-22 Sage Therapeutics, Inc. 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
SMT202100229T1 (it) 2013-07-19 2021-05-07 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
SMT202100048T1 (it) 2013-08-23 2021-03-15 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
TW201625660A (zh) * 2014-09-17 2016-07-16 普瑞弗克斯公司 Ｃ－２０類固醇化合物、其組成物及用於治療包含震盪之創傷性腦損傷（ｔｂｉ）的用途
JP6742308B2 (ja) 2014-10-16 2020-08-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
AU2015331749A1 (en) 2014-10-16 2017-05-04 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ES2793237T3 (es) 2014-11-27 2020-11-13 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
CN109689673B (zh) 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
CN115974954A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350739B1 (en) * 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
US9446051B2 (en) * 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®

Also Published As

Publication number Publication date
EP3416651A1 (en) 2018-12-26
WO2016209847A1 (en) 2016-12-29
AR105075A1 (es) 2017-09-06

Similar Documents

Publication Publication Date Title
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
CO2021007068A2 (es) Degradadores de irak y usos de los mismos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
UY36530A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2022006862A (es) Inhibidores duales de magl y faah.
CL2016002463A1 (es) Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
ECSP18091065A (es) Ésteres de oxaborol y sus usos
BR112016017886A8 (pt) grelina ou variantes ou derivados da mesma, e, usos da grelina
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221125

RDES Application refused

Effective date: 20230904